Navigation Links
Ironwood Announces Linaclotide European Licensing Agreement with Almirall
Date:5/4/2009

- Ironwood Will Receive Up To $55 Million in Near Term Payments -

CAMBRIDGE, Mass., May 4 /PRNewswire/ -- Ironwood Pharmaceuticals, Inc. today announced that the company has entered into an out-licensing agreement with Laboratorios Almirall, S.A. for European rights to develop and commercialize the investigational compound linaclotide for the treatment of irritable bowel syndrome with constipation (IBS-C) and other gastrointestinal conditions. This agreement is a continuation of Ironwood's strategy to develop and market its products in the United States while forming partnerships to accelerate delivery to patients in other territories.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081006/NEM080ALOGO )

Under the terms of the agreement, Almirall will provide Ironwood with up to $55 million in near-term payments, including a $40 million upfront licensing fee. Pre-commercial licensing fees and milestone payments total $95 million. In addition, Ironwood will receive escalating royalties on linaclotide sales. Almirall will be responsible for activities relating to regulatory approval and commercialization, as well as expenses for the European market. Ironwood continues to retain all rights to linaclotide outside of North America and Europe.

"We are very pleased to be joining forces with Almirall to develop and commercialize linaclotide for the millions of patients in Europe who suffer from IBS-C and currently lack adequate therapies. Almirall presented us with the best strategy to rapidly and effectively deliver linaclotide to the market, and terms that, should linaclotide meet our expectations, allow us to share approximately half of the long term value of the product," said Peter Hecht, Ironwood's chief executive office
'/>"/>

SOURCE Ironwood Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results
2. Ironwood and Forest to Present Positive Data From Linaclotide Phase 2b IBS-C Study at ACG Annual Scientific Conference
3. Ironwood Raises $50 Million to Advance Linaclotide Through Phase 3
4. Ironwood and Collaborators Present Preclinical Data Demonstrating That Cyclic GMP Alleviates Intestinal Pain
5. Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
8. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... , Jan. 14, 2014 HeartWare International, ... innovator of less invasive, miniaturized circulatory support technologies that ... announced that it expects revenues for the fourth quarter ... full-year 2013 revenues to approximately $208 million. ...
(Date:1/14/2014)... Dynamic Healthcare Services, Inc. ("DHS"), a portfolio company of ... Home Medical Equipment, Inc. ("Progressive") of Clarion, PA ... acquisition were not disclosed. Progressive is a ... range of sleep, mobility, and respiratory products to customers in ...
(Date:1/14/2014)... Jan. 14, 2014 NineSigma , Inc., the ... Innovation Leadership Summit , May 14-16, 2014 at ... Cleveland Ohio . This is ... committed to breakthrough achievements through open innovation. Participants will ...
Breaking Medicine Technology:HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 2Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 3Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 4
... Medical, Inc. (Nasdaq: NXTM ), a leading manufacturer ... financial results for the first quarter ended March 31, 2011 ... financial markets. NxStage will also host a conference ... 2011 to discuss its first quarter financial results. To listen ...
... Novartis Pharmaceuticals Corporation ("Novartis") announced today that the ... Advisory Committee (ODAC) recommended approval of Afinitor® (everolimus) ... neuroendocrine tumors (NET) of pancreatic origin. ... from the everolimus RADIANT (RAD001 In Advanced Neuroendocrine ...
Cached Medicine Technology:NxStage® to Report First Quarter Fiscal 2011 Financial Results 2Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 2Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 3Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 4Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 5Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 6Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 7Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 8Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 9Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 10
(Date:4/24/2014)... negative and stressful outcomes for parents who have a ... illness, says a recent study led by a researcher ... are numerous and life-changing and stress levels high, the ... research reported positive outcomes as well, a phenomenon known ... recent issue of the American Journal of Orthopsychiatry ...
(Date:4/24/2014)... 2014 ,Take me out to the ballgame, doesn,t ... chips. The more likely culprits include French fries, soda ... for children who play youth baseball, eating unhealthy food ... problems, according to researchers at Wake Forest Baptist Medical ... of Childhood Obesity , found that high-calorie snacks ...
(Date:4/24/2014)... will bring together national experts to discuss solutions ... inaugural Brain Health Summit, titled "The Human Brain: ... Dr. Sandra Bond Chapman, founder and chief director ... Grassley (R-IA), U.S. Representative Chaka Fattah (D-PA) and ... Early Learning, U.S. Department of Education. The day ...
(Date:4/24/2014)... Fibroblasts, cells long thought to be boring and irrelevant, ... with heart disease. , Researcher Dr Milena Furtado, and ... at Monash University, found the heart cell fibroblast is ... for a healthy beating heart. , In research published ... found that cardiac fibroblasts are unique cells due to ...
(Date:4/24/2014)... of prescription opioid overdose deaths was outlined yesterday in ... leaders of agencies in the U.S. Department of Health ... care providers to expand their use of medications to ... a number of misperceptions that have limited access to ... medications can be used in combination with behavior therapies ...
Breaking Medicine News(10 mins):Health News:Parents of severely ill children see benefits as caregivers, says study 2Health News:Take the bat, leave the candy 2Health News:Inaugural Brain Health Summit focuses on brain resilience and regeneration 2Health News:Boring cells could hold the key to heart disease 2Health News:HHS leaders call for expanded use of medications to combat opioid overdose epidemic 2Health News:HHS leaders call for expanded use of medications to combat opioid overdose epidemic 3Health News:HHS leaders call for expanded use of medications to combat opioid overdose epidemic 4
... The California Veterinary Medical Association (CVMA) warns ... when procedures such as teeth cleaning or therapeutic ... is because special training is necessary and some ... and may require anesthesia. Under California law, only ...
... someday yield therapies to restore sight, experts suggest , , ... plays a major role in two forms of childhood ... researchers. , The discovery of the link between the ... retinitis pigmentosa is important because it pinpoints a new ...
... experts warn , , THURSDAY, March 5 (HealthDay News) -- ... have positive or neutral attitudes toward people who are ... prospective patients, a new study has found. , "Essentially, ... weight bias, and there are negative attitudes toward obese ...
... a national provider of healthcare information technology outsourcing, ... Total Security Program which is designed to offer ... of security services that assess, remediate and monitor ... The Program goes beyond regulated compliance requirements to ...
... Realize New Executive LeadershipKOBE, Japan, March 5 ... leading medical diagnostics instrument manufacturer and laboratory information ... Sysmex Corporate and its subsidiaries in the Americas, ... Kazuya Obe will return to Sysmex Corporate after ...
... headed by Dr. Tom Feasby, Dean of UCalgary,s Faculty ... countries in the number of diagnostic imaging devices, more ... times. The study,s authors say it is critical to ... "This study shows there are important deficiencies in the ...
Cached Medicine News:Health News:Consumers Beware: Unlicensed Care of Animals May Cause Health Problems and Increased Costs 2Health News:Retinal Gene Is Linked to Childhood Blindness 2Health News:Bias Against Obesity Is Found Among Future Dietitians 2Health News:Bias Against Obesity Is Found Among Future Dietitians 3Health News:Phoenix Health Systems Launches Total Security Program for the Healthcare Industry 2Health News:Sysmex Corporation Announces Organizational Changes 2Health News:Lack of strategies to manage MRI wait lists a key reason for excessive wait times 2
... Mesh Self-Forming Plug is a mesh plug ... well as primary inguinal hernias and femoralhernias. ... defect and fills it completely. Premilene Mesh ... of the established Premilene Mesh. The plug ...
... The Celsius Control System provides ... can safely,and rapidly lower patient ... target temperature and,rewarm patients to ... System consists of an endovascular,catheter, ...
... , it maximizes use by allowing ... it, while the third lamp is ... care in mind, it includes universal ... An excellent choice for hospital operating ...
... Perfectly balanced, the patented Orion incorporates ... that illuminates brilliantly. The fully adjustable ... designed to sit low on the brow, ... vision. Two clips on the headband ...
Medicine Products: